Added to YB: 2026-09-17
Pitch date: 2026-09-14
SOPH [neutral]
SOPHiA GENETICS SA
Author Info
Business Model Mastery is a daily, easily digestible guide to mastering how businesses work. Build a mental database of companies, compare opportunities, and quickly assess business models with confidence—gaining an edge over other market participants. Sign up for the newsletter.
Company Info
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Market Cap
$669.1M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.96
P/E
-6.78
EV/Sales
7.23
Sector
Health Care Technology
Category
growth
SOPHiA GENETICS Stock Analysis: The Platform Is Growing Fast. The Business Still Has to Prove It Can Make Money.
SOPH (overview): SOPHiA GENETICS’ genomic-analysis platform is gaining traction: Q2 revenue rose 27%, US revenue approximately 64%, analysis volume 22% and NDR reached 117%, with adjusted gross margin above 72%. Yet normalized owner earnings remain an estimated negative $35M-$45M annually, and recent dilution is material. At $5.50-$6.50, successful conversion to durable profitability could support 8%-10% annual returns; the key question is whether that can occur without further major equity issuance.
Read full article (4 min)